Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839472 | 0.88 | UTS2R (0.44) | SMN1; SMN2LMNAMEN1KMT2APOLB | |
| SCHEMBL6096149 | 0.88 | UTS2R (0.50) | TSHR | |
| SCHEMBL6093542 | 0.87 | UTS2R (0.37) | SMN1; SMN2ALDH1A1TSHRRECQLKMT2A | |
| SCHEMBL6093947 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTUSP5LMNAMEN1 | |
| SCHEMBL6097929 | 0.84 | UTS2R (0.40) | SMN1; SMN2LMNAMEN1KMT2APOLB | |
| SCHEMBL6093569 | 0.83 | UTS2R (0.46) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL6744733 | 0.82 | UTS2R (0.44) | HRH3SMN1; SMN2MAPTUSP5LMNA | |
| SCHEMBL6191929 | 0.82 | HRH3 (0.41) | HRH3SMN1; SMN2MAPTALDH1A1TSHR | |
| SCHEMBL6741880 | 0.82 | UTS2R (0.44) | HRH3SMN1; SMN2MAPTUSP5LMNA | |
| SCHEMBL6845059 | 0.82 | ALDH1A1 (0.43) | HRH3SMN1; SMN2MAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019008-B2 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | claimed |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | SMITHKLINE BEECHAM CORPORATION | 2005-09-08 | — | — | US | claimed |
| EP-1381365-A4 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | claimed |
| EP-1381365-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-21 | — | — | EP | claimed |
| WO-2002078707-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-7019008-B2 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | SMITHKLINE BEECHAM CORPORATION | 2005-09-08 | — | — | US | disclosed |
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138224-A1 | Pyrrolidine sulfonamides | UTS2R, PRSS2, PRSS8 | HRH3 1428/4885SMN1; SMN2 1697/4885MAPT 2548/4885 |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | UTS2R, PLAUR, NTSR2 | HRH3 1315/4885SMN1; SMN2 2254/4885MAPT 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.